Mirror Biologics

Immunomodulatory Vaccines and Immunotherapy Treatments

Health Tech & Life Sciences

Private

Company Overview

Snapshot

Founded in May 2004 by Dr. Michael Har-Noy, Mirror Biologics operates with 1–10 employees. The company has raised $42.5 million across three funding rounds. Mirror Biologics initiated its AlloStim® Phase IIB Clinical Trial (STIMVAX) in patients with metastatic colorectal cancer in July 2021.

Business overview

Mirror Biologics is an international biopharmaceutical company focused on developing and manufacturing next-generation immunotherapy products. The company's core technology involves living immune cells, originally spun out from Hadassah-Hebrew University Medical Center. Mirror Biologics develops immunomodulatory vaccines and immunotherapy treatments, including its patented immune cell, AlloStim®, designed to educate and modify a patient’s immune system to target cancers and infectious organisms. Its Mirror Effect® technology platform expands immunotherapy indications beyond first-generation CAR-T and checkpoint inhibitor approaches, serving the health tech and life sciences sectors.

Strategic signal

In July 2021, Mirror Biologics announced the initiation of its AlloStim® Phase IIB Clinical Trial (STIMVAX) for patients with metastatic colorectal cancer. This development signals the company's continued progress in advancing its cell-based immunotherapy pipeline, demonstrating a commitment to clinical validation and potentially offering new treatment avenues for challenging diseases.

Company Intelligence Q&A

When was Mirror Biologics founded?: Mirror Biologics was founded in May 2004 by Dr. Michael Har-Noy.
What is Mirror Biologics' primary focus?: Mirror Biologics specializes in the development and manufacturing of next-generation immunotherapy products, utilizing living immune cells to treat and prevent diseases.
What significant clinical trial did Mirror Biologics initiate?: In July 2021, Mirror Biologics initiated the AlloStim® Phase IIB Clinical Trial (STIMVAX) for patients with metastatic colorectal cancer.
What is the total capital raised by Mirror Biologics?: Mirror Biologics has raised a total of $42.5 million across three funding rounds.
What was a key development for Mirror Biologics in May 2020?: In May 2020, Mirror Biologics and Immunovative Therapies announced the publication of the technical rationale for developing a universal anti-viral vaccine.

External links

Mirror Biologics — full profile (machine-readable)

Mirror Biologics is an international biopharmaceutical company specialized in development and manufacturing of next generation immunotherapy products where the active ingredients are living immune cells. Its technology originally spun out from Hadassah-Hebrew University Medical Center in Jerusalem. The company operates a 21 CFR 1271-compliant blood donor and cell processing center and conduct research and development on the design and testing of novel bioreactors and commercial manufacturing systems. Its next generation immunotherapy programs aim to harness the power of the human immune system to treat and prevent disease. The company has developed a patented immune cell, called AlloStim®, with powerful immunomodulatory properties that is used to educate and modify a patients’ own immune system to enable it to identify and destroy cancers and infectious organisms and to reprogram immune systems weakened by age or chronic infection. Its immunomodulatory vaccine development programs are based upon its novel Mirror Effect® technology platform which is able to imprint a re-programmed immune response over an existing failed immune response of a diseased or elderly patient. This novel technology platform expands the indications and type of patients that might benefit from immunotherapy approaches beyond first generation CAR-T and checkpoint inhibitor approaches. Mirror Biologics acquired all the assets of Immunovative Therapies.

Facts
Name	Mirror Biologics
One-liner	Immunomodulatory Vaccines and Immunotherapy Treatments
Type	Startup
Primary sector	Health Tech & Life Sciences
Founded	2004
Employees	1-10
Employees (exact)	9
HQ / location	Jerusalem, Agudat Sport HaPo'el Road 1, Jerusalem, Israel, Jerusalem District
Product stage	Clinical Trial
Website	https://www.mirrorbio.com/
LinkedIn	https://www.linkedin.com/company/13180493
Crunchbase	immunovative-therapies
IL Registrar	513529792

Facts

Name

Mirror Biologics

One-liner

Immunomodulatory Vaccines and Immunotherapy Treatments

Type

Startup

Primary sector

Health Tech & Life Sciences

Founded

2004

Employees

1-10

Employees (exact)

HQ / location

Jerusalem, Agudat Sport HaPo'el Road 1, Jerusalem, Israel, Jerusalem District

Product stage

Clinical Trial

Website

https://www.mirrorbio.com/

https://www.linkedin.com/company/13180493

Crunchbase

immunovative-therapies

IL Registrar

513529792

Classification
Sectors	Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development
Core technology	Biologicals, Cells
Target customers	Healthcare & Life Sciences, Life Sciences, Biotechnology, Pharmaceuticals
Business models	B2B
Tags	biotechnology, cancer, infectious-disease, cell-therapy, oncology, immunotherapy, biopharmaceutical, immunology, stem-cells, patients, pharma-companies, vaccines

Classification

Sectors

Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development

Core technology

Biologicals, Cells

Target customers

Healthcare & Life Sciences, Life Sciences, Biotechnology, Pharmaceuticals

Business models

B2B

Date	Round	Amount	Investors
May 2006	Seed	$500K
Jan 2022	A Round	$30M	Undisclosed Investor(s)
Jan 2012	Undisclosed Round	$12M	Misgav Technology Center, The Trendlines Group

Date	Source	Summary
Jul 9, 2021	www.pr.com	Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase IIB Clinical Trial (STIMVAX) in Patients with Metastatic Colorectal Cancer - PR.com
Jun 30, 2020	themedialine.org	Israeli Company Hopes Universal Anti-Viral Vaccine Will Protect Elderly From COVID-19 - The Media Line
Jun 23, 2020	www.prnewswire.com	Immunovative Therapies and Mirror Biologics Announce US FDA Clearance of a Universal Anti-Viral Vaccine Phase I/II Clinical Trial for Healthy Elderly Adults
May 28, 2020	www.pharmiweb.com	Mirror Biologics and Immunovative Therapies announce publication of the technical rationale for development of a universal anti-viral vaccine targeted
May 19, 2020	european-biotechnology.com	Vaccine to protect from any viral infection
Mar 6, 2019	www.genengnews.com	Navigating the Challenges of Cell-Based Immunotherapies
Jan 29, 2019	www.israel21c.org	Could an immunotherapy treatment from Israel cure cancer?
Dec 10, 2018	www.prnewswire.com	Immunovative Therapies to Present at Biotech Showcase™ 2019 in San Francisco
Nov 23, 2018	www.biospace.com	Deep Dive: Immunovative Therapies' Next-Generation Cancer Vaccine Could Change the Game BioSpace
Nov 14, 2016	immuno-oncologynews.com	Clinical Trial to Assess Next Generation Immunotherapy in...
Nov 7, 2016	www.prnewswire.com	CryoVax(R) : Next Generation Immunotherapy for Metastatic Colorectal Cancer Begins USA Phase IIb Clinical Trial
May 24, 2011	www.globes.co.il	Immunovative Therapies to go public through US reverse merger
Aug 14, 2009	www.prweb.com	CryoStim™ Cancer Treatment to Begin FDA Clinical Trials September 1, 2009
Jul 15, 2007	www.israel21c.org	'Angry' cell treatment harnesses power of immune system to destroy cancer cells

Mirror Biologics

Company Overview

Snapshot

Business overview

Strategic signal

Company Intelligence Q&A

External links

Generate Slim Page